Emergent Biosolutions, Inc. (EBS) News
Filter EBS News Items
EBS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EBS News Highlights
- EBS's 30 day story count now stands at 5.
- Over the past 21 days, the trend for EBS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- MD, AGE and DRUG are the most mentioned tickers in articles about EBS.
Latest EBS News From Around the Web
Below are the latest news stories about EMERGENT BIOSOLUTIONS INC that investors may wish to consider to help them evaluate EBS as an investment opportunity.
Emergent (EBS) Acquires Worldwide Rights to Smallpox AntiviralEmergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix. |
Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All AgesGAITHERSBURG, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® (brincidofovir), the first oral antiviral approved by the U.S. Food and Drug Administration (FDA) for all age groups for the treatment of smallpox, from Chimerix. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. |
A Emergent BioSolutions Inc. (NYSE:EBS) insider increased their holdings by 31% last yearLooking at Emergent BioSolutions Inc.'s ( NYSE:EBS ) insider transactions over the last year, we can see that insiders... |
Emergent (EBS) Initiates Study on Lassa Virus Vaccine CandidateEmergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever. |
Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine CandidateGAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection. Emergent and CEPI (the Coalition for Epidemic Preparedness Innovations) are co-funding this program. “Over the last 24 years, Emergent’s mission |
10 Best Stocks to Buy According to Yale Finance ProfessorIn this article, we will be taking a look at the top 10 stocks to buy according to Roger Ibbotson’s Zebra Capital. To skip our detailed analysis, you can go directly to see 5 Stocks to Buy According to Roger Ibbotson’s Zebra Capital. Ibbotson’s top 10 stock picks lost 9.5% since the end of the first […] |
Emergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound?Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
3 Top Monkeypox Stocks to Buy Right NowWith cases of a frightening disease spreading to all 50 states, it’s now time to consider the top monkeypox stocks to buy right now. |
7 Monkeypox Vaccine Stocks to Buy Before They Shoot HigherThese monkeypox stocks could be among the best choices to buy in August. |
FDA Issues Warning Letter For Emergent Bio's Manufacturing FacilityThe FDA issued a warning letter to Emergent BioSolutions Inc (NYSE: EBS), citing certain deficiencies at the company's troubled manufacturing facility in Baltimore, Maryland. The FDA pointed to equipment cleaning and maintenance deficiencies to prevent drug product contamination. Reuters reported that the agency also recommended that the company review its quality control process. Related: Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract. Emergent had said the FDA had last |